Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)
This ongoing clinical trial SWIFT-IPF is evaluating functional assessment of small airways disease in idiopathic pulmonary fibrosis and is c…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 trial of MN-001 (tipelukast) in idiopathic pulmonary fibrosis has completed enrollment; results detailing safety, tolerability, and …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy [EARLY_Phase 1]
A Phase 1 trial for REGEND007 cell therapy targeting idiopathic pulmonary fibrosis is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis [Phase 2]
Phase 2 study of BI 1839100 for cough in idiopathic pulmonary fibrosis or progressive pulmonary fibrosis has been terminated.
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure [Phase 1, Phase 2]
A Phase 1/2 clinical trial is recruiting to evaluate lung and bone marrow transplantation for lung and bone marrow failure, including idiopa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis [NA]
A clinical trial evaluating azithromycin for management of acute exacerbation in idiopathic pulmonary fibrosis, currently recruiting at Assi…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
A pilot clinical trial evaluating body composition measurement using bioelectrical impedance analysis and muscle ultrasound in patients with…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Dose-Escalation Study of Artesunate Patients With IPF [Phase 1]
A Phase 1 dose-escalation trial of artesunate in idiopathic pulmonary fibrosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: CAR-DC for End-Stage IPF [Phase 1]
Phase 1 clinical trial update indicates the CAR-DC therapy for end-stage idiopathic pulmonary fibrosis is not yet recruiting.
-
EMA approval · 2026-01-06EMA Authorised: Ofev (nintedanib) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised a label expansion for Ofev (nintedanib) to cover additional interstitial lung diseases, including s…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Genentech Xenon MRI Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 trial of Xenon MRI for idiopathic pulmonary fibrosis has posted results; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Mechanisms of Familial Pulmonary Fibrosis
Clinical trial update investigating the mechanisms underlying familial pulmonary fibrosis, currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF [Phase 1]
Phase I trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AGMB-447 in healthy participants and individuals with…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Detection of Early Idiopathic Pulmonary Fibrosis
Temple University is conducting an ongoing clinical trial to detect early idiopathic pulmonary fibrosis, as listed on ClinicalTrials.gov.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) [Phase 1]
Phase 1/IIa clinical trial evaluating injections of human umbilical cord-derived mesenchymal stem cells for idiopathic pulmonary fibrosis wa…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis [Phase 2]
Phase II randomized, double-blind study evaluating HRS-9813 for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung di…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole [Phase 3]
A Phase 3 clinical trial is recruiting to assess the addition of lansoprazole to treatment for idiopathic pulmonary fibrosis.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]
Phase 3 trial evaluating LYT-100 (deupirfenidone) versus pirfenidone for Idiopathic Pulmonary Fibrosis; currently not yet recruiting.
-
CLINICAL_TRIALS safety_alert · 2025-12-19Clinical Trial Update: Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib
This clinical trial update discusses diarrheal adverse events observed in Caucasian patients with idiopathic pulmonary fibrosis treated with…
-
EMA approval · 2025-12-19EMA Authorised: Pirfenidone Viatris (Pirfenidone) — Viatris Limited
EMA authorised Pirfenidone Viatris as a generic version of pirfenidone for idiopathic pulmonary fibrosis in the European Union, expanding ac…
-
EMA approval · 2025-12-10EMA Authorised: Esbriet (Pirfenidone) — Roche Registration GmbH
The European Medicines Agency authorised Esbriet (pirfenidone) for idiopathic pulmonary fibrosis under Roche Registration GmbH, with decisio…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis [NA]
Clinical trial update describing a study on partitioned training for patients with idiopathic pulmonary fibrosis; the trial is currently act…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis [Phase 2]
A multicenter Phase 2 trial evaluating the efficacy, safety, and tolerability of HZN-825 in idiopathic pulmonary fibrosis has been terminate…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Identification of Palliative Care Needs and Prognostic Factors of Survival in Tailoring Appropriate Interventions in Advanced Oncological, Renal and Pulmonary Diseases
A completed study assessing palliative care needs and survival prognostic factors in patients with advanced cancer, chronic kidney disease, …
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
A Phase 2 trial evaluating oral INS018_055 in idiopathic pulmonary fibrosis has completed, and results have been posted.